HER2-POSITIVE BREAST CANCER

This study tested whether a combination of two drugs, ASLAN001 and capecitabine, could shrink brain tumors in people with HER2-positive breast cancer whose brain metastases had grown after radiation therapy. Only 3 participants were enrolled before the study was stopped early. Th…

This study tested a new drug called BDC-1001, alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer who had already tried other treatments including trastuzumab deruxtecan. The goal was to see if the drug could shrink tumors. However, the st…

This study tested a new drug called BDC-1001, alone or with another drug (nivolumab), in people with advanced HER2-positive solid tumors (like breast, colorectal, or stomach cancer). The goal was to see if it was safe and could shrink tumors. The trial was stopped early, so resul…

This study looked at whether women with a certain type of early-stage HER2-positive breast cancer could avoid surgery if their tumors completely disappeared after standard chemotherapy and anti-HER2 drugs. Only 5 women enrolled before the study was stopped. The goal was to see if…

This early-phase study tested whether combining three drugs (tucatinib, trastuzumab, capecitabine) with precise radiation could control brain tumors from HER2-positive breast cancer. Only one person enrolled before the trial was stopped. The main goal was to check safety and side…

This study tested whether giving heart medications (carvedilol and empagliflozin) before or alongside HER2-targeted therapy could prevent heart damage in people with HER2-positive breast cancer. The trial aimed to see if it was possible to enroll enough patients and if the drugs …

This study looked at whether early MRI scans can show how well the immune system is fighting HER2-positive breast cancer after one round of treatment. Researchers observed 13 patients before and after anti-HER2 therapy. The goal was to see if changes on MRI match the level of imm…